口服胰岛素肠溶聚合物脂质杂化纳米粒的制备与评价
Preparation and evaluation of an oral insulin enteric preparation based on polymer-lipid hybrid nanoparticles
-
摘要: 为了提高胰岛素的口服生物利用度，本研究以聚乙二醇聚乳酸共聚物(PEG-PLA)为高分子载体材料、磷脂s75为脂质材料、Eudragit L100为肠溶材料制备口服胰岛素肠溶聚合物脂质杂化纳米粒(INS-NPs L100)，并对其体内外性能进行评价。采用W/O/W复乳溶剂挥发法制备胰岛素聚合物脂质杂化纳米粒(INS-NPs)，以包封率、粒径和释药行为为评价指标，采用单因素法对处方进行优化；将最优INS-NPs与肠溶材料Eudragit®； L100混合制备成INS-NPs L100，并对其形态、体外释放及健康大鼠灌胃后的降血糖作用进行评价。以最优处方制备的INS-NPs包封率为(62.18±4.51)%，平均粒径为(225.2±94.3)nm，多分散系数为0.191±0.068，Zeta电位为-(14.84±1.26)mV。包裹肠溶材料后所制备的INS-NPs L100，在pH 1.0盐酸溶液中2 h累积释放量为8.01%，在pH 6.8的磷酸盐缓冲液中6 h累积释放量为67.31%。将所制备的INS-NPs L100经口给予健康大鼠(38 IU/kg)后，具有明显的持续降血糖作用，3.5 h时血糖浓度可降至初始值的76%。实验结果表明，本研究所制备的INS-NPs L100可有效减缓胰岛素在胃液中的释放速度，提高蛋白在胃肠道中的稳定性，为多肽、蛋白类药物口服给药提供了新的研究思路。
-
关键词:
- 胰岛素 /
- 口服肠溶制剂 /
- 聚合物-脂质杂化纳米粒 /
- 制备
Abstract: To improve the oral bioavailability of insulin, an insulin-loaded enteric polymer-lipid hybrid nanoparticles(INS-NPs L100)was prepared using methoxy PEG-poly(D, L-lactide)(PEG-PLA), phospholipid s75 and Eudragit L100; in vitro and in vivo behaviors of INS-NPs L100 were evaluated. Insulin-loaded polymer-lipid hybrid nanoparticles(INS-NPs)were prepared by W/O/W double emulsion solvent evaporation method. INS-NPs formulation was optimized by single factor experiment using encapsulation efficiency, particle size, and in vitro release behavior of the corresponding INS-NPs L100 as evaluation indexes. The morphology, in vitro drug release profile and hypoglycemic effect of the INS-NPs L100 using the optimal INS-NPs and Eudragit® L100(used as enteric polymer)were assessed. The results showed that the encapsulation efficiency of the optimal INS-NPs was(62. 18±4. 51)%. The average particle size, PDI and Zeta potential was(225. 2±94. 3)nm, 0. 191±0. 068, and -(14. 84±1. 26)mV, respectively. The cumulative drug release from the INS-NPs L100 was only 8. 01% at 2 h in pH 1. 0 HCl solution, exhibiting a slow drug release behavior; while the drug release from INS-NPs L100 was 67. 31% at 6 h in phosphate buffer of pH 6. 8. Mereorer, after oral administration of INS-NPs L100 with a dose of 38 IU/kg, the blood glucose concentration of healthy rats was reduced to 76% of the initial values at 3. 5 h, exhibiting a sustained hypoglycemic effect. In summary, the INS-NPs L100 prepared in this study could effectively decrease the release rate of insulin in gastric juice, improve the stability of protein in the gastrointestinal tract, and provide a new approach for the oral administration of peptides and protein drugs.-
Keywords:
- insulin /
- oral enteric preparation /
- polymer-lipid hybrid nanoparticles /
- preparation
-
-
[1] Wang L,Gao P,Zhang M,et al.Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013[J].JAMA,2017,317(24):2515-2523. [2] Li CY,Huang WL,Qian H.Advances in the research of long-acting strategy of insulin and GLP-1 analogs[J].J China Pharm Univ(中国药科大学学报),2018,49(6):660-670. [3] Wong CY,Al-Salami H,Dass CR.Microparticles,microcapsules and microspheres:a review of recent developments and prospects for oral delivery of insulin[J].Int J Pharm,2018,537(1/2):223-244. [4] Deutel B,Laffleur F,Palmberger,et al.In vitro characterization of insulin containing thiomeric microparticles as nasal drug delivery system[J].Eur J Pharm Sci,2016,81:157-161. [5] Ledet G, Graves RA, Bostanian LA, et al. A second-generation inhaled insulin for diabetes mellitus[J].Am J Health-Syst Pharm,2015,72(14):1181-1187. [6] Cai L,Zhu Z.Progress in non-invasive routes for insulin preparations[J].J China Pharm Univ(中国药科大学学报),2007,38(2):105-107. [7] Geho WB,Rosenberg LN,Schwartz SL,et al.A single-blind,placebo-controlled,dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus[J].J Diabetes Sci Technol,2014,8(3):551-559. [8] Eldor R,Arbit E,Corcos A,et al.Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes:a pilot study[J].PLoS One,2013,8(4):59524. [9] Li CY,Huang WL,Qian H.Advances in the research of long acting strategy of insulin and GLP-1 analogs[J].J China Pharm Univ(中国药科大学学报),2018,49(6):660-670. [10] Grigoras AG. Polymer-lipid hybrid systems used as carriers for insulin delivery[J].Nanomedicine,2017,13(8):2425-2437. [11] Sun S,Liang N,Yamamoto H,et al.pH-sensitive poly(lactide-co-glycolide)nanoparticle composite microcapsules for oral delivery of insulin[J].Int J Nanomed,2015,10:3489-3498. [12] Ben-Shabat S,Kumar N,Domb AJ.PEG-PLA block copolymer as potential drug carrier:preparation and characterization[J].Macromol Biosci,2006,6(12):1019-1025. [13] Liu J,Gong T,Wang C,et al.Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles:preparation and characterization[J].Int J Pharm,2007,340(1/2):153-162. [14] García-Díaz M,Foged C,Nielsen HM.Improved insulin loading in poly(lactic-co-glycolic)acid(PLGA)nanoparticles upon self-assembly with lipids[J].Int J Pharm,2015,482(1/2):84-91. [15] Ghasemi R,Abdollahi M,Emamgholi Zadeh E,et al.mPEG-PLA and PLA-PEG-PLA nanoparticles as new carriers for delivery of recombinant human growth hormone(rhGH)[J].Sci Rep,2018,8(1):9854. [16] Gou J,Feng S,Liang Y,et al.Polyester-solid lipid mixed nanoparticles with improved stability in gastro-intestinal tract facilitated oral delivery of larotaxel[J].Mol Pharm,2017,14(11):3750-3761. -
期刊类型引用(5)
1. 刘黎瑶，张蕊，张守庆，廉文静，丛方地. 微柱离心-HPLC测定胰岛素脂质体的包封率. 中国药学杂志. 2022(03): 214-219 . 
百度学术
2. 陶晓倩，付慧敏，乔子桐，张强，包子威，程岚，张纯刚. 肠溶性软胶囊的研究进展. 中国药房. 2022(07): 891-896 . 百度学术
3. 赖志昆，冯其茂，王骕，胡晓贞. 黄芪甲苷脂质聚合物纳米粒对缺血再灌注损伤诱导大鼠模型的影响. 中国医药导报. 2022(11): 25-29 . 百度学术
4. 王占乐，臧林泉. 基于介孔碳纳米粒包载胰岛素实现口服递药的研究. 中国临床药理学杂志. 2021(07): 863-867 . 百度学术
5. 王思琦，张咏馨，赵元骞，梁旭，吴正红，季鹏. 高口服生物利用度胰岛素纳米制剂的研究进展. 第二军医大学学报. 2020(09): 1027-1030 . 百度学术
其他类型引用(3)
计量
- 文章访问数: 711
- HTML全文浏览量: 4
- PDF下载量: 1125
- 被引次数: 8
下载:
